Zimmer Biomet (NYSE:ZBH) Price Target Lowered to $112.00 at Barclays

Zimmer Biomet (NYSE:ZBH) had its price objective decreased by Barclays from $118.00 to $112.00 in a research note released on Monday morning,Benzinga reports. Barclays currently has an underweight rating on the medical equipment provider’s stock.

Other research analysts also recently issued research reports about the stock. Truist Financial upped their price objective on shares of Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a report on Wednesday, December 18th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Friday. Wells Fargo & Company lifted their price target on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Stifel Nicolaus increased their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Finally, Royal Bank of Canada cut their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Price Performance

ZBH stock opened at $100.40 on Monday. Zimmer Biomet has a 1 year low of $99.67 and a 1 year high of $133.90. The stock has a market capitalization of $19.99 billion, a PE ratio of 22.56, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02. The company’s 50-day moving average is $107.34 and its 200-day moving average is $108.07. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.70.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the firm earned $2.20 earnings per share. Equities research analysts expect that Zimmer Biomet will post 8.25 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s payout ratio is 21.57%.

Institutional Trading of Zimmer Biomet

Large investors have recently bought and sold shares of the company. Equity Investment Corp purchased a new position in Zimmer Biomet during the 3rd quarter valued at about $70,104,000. Hotchkis & Wiley Capital Management LLC boosted its position in shares of Zimmer Biomet by 49.1% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock worth $189,161,000 after purchasing an additional 577,320 shares in the last quarter. Van ECK Associates Corp grew its stake in shares of Zimmer Biomet by 12.4% in the 3rd quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock worth $391,239,000 after buying an additional 411,163 shares during the last quarter. Thompson Siegel & Walmsley LLC purchased a new position in Zimmer Biomet during the third quarter valued at $41,588,000. Finally, Raymond James Financial Inc. bought a new position in Zimmer Biomet in the 4th quarter worth about $21,234,000. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.